QCG
MLYS icon

Quadrant Capital Group’s Mineralys Therapeutics MLYS Stock Holding History

Quadrant Capital Group’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-5
Closed -$136 – 2045
2026
Q1 		$136 Sell
5
-3
-38% -$88 ﹤0.01% 2683
2025
Q4 		$291 Sell
8
-2
-20% -$80 ﹤0.01% 2675
2025
Q3 		$380 Buy
+10
New +$216 ﹤0.01% 2631
2025
Q2 		– Sell
-112
Closed -$1.78K – 2101
2025
Q1 		$1.78K Sell
112
-17
-13% -$196 ﹤0.01% 2528
2024
Q4 		$1.59K Hold
129
– – ﹤0.01% 2527
2024
Q3 		$1.56K Hold
129
– – ﹤0.01% 2528
2024
Q2 		$1.51K Hold
129
– – ﹤0.01% 2514
2024
Q1 		$1.67K Hold
129
– – ﹤0.01% 2534
2023
Q4 		$1.11K Buy
+129
New +$1.01K ﹤0.01% 2546

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Quadrant Capital Group's MLYS Position: Q2 2026 in Review

Quadrant Capital Group sold out of Mineralys Therapeutics (MLYS) in Q2 2026, closing a stake of 5 shares — an estimated $136 sold.

Quadrant Capital Group first reported a position in MLYS in Q4 2023 and held it in 9 quarters. The position peaked at $1.78K in Q1 2025. 226 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Quadrant Capital Group reported no remaining Mineralys Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Quadrant Capital Group sold 5 Mineralys Therapeutics shares in Q2 2026, an estimated $136.
  • Quadrant Capital Group first reported a position in Mineralys Therapeutics in Q4 2023 and held it in 9 quarters.
  • Quadrant Capital Group's Mineralys Therapeutics position peaked at $1.78K in Q1 2025.
  • 226 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Quadrant Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.